

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Burchardt, et al.

Group No.:

Serial No.: National Stage Filing of PCT/EP99/08181

Examiner:

Filed: Herewith

For: Phosphinate Peptide Analogs for the Treatment of Fibrotic Disorders

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT


Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 41,670

Telephone: (203) 812-3964

Date: APR 30 2001


Jerrie L. Chiu
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516